Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
It’s not sports! Overzealous fans should respect their idols
Experts in China studies impressed by city’s transformation during site visits
Sunday
- Subscribe
Related News
Home » Business » Manufacturing
Buying rival to cost Merck US$41.1b
By Phil Serafino |
March 10, 2009, Tuesday
|
Print Edition
Print Edition
MERCK & Co has agreed to buy rival United States drug maker Schering-Plough Corp for US$41.1 billion in cash and stock to get a larger experimental pipeline and products unhindered by imminent patent losses.
Schering-Plough holders will get US$23.61 a share, a 34-percent premium to the closing stock price last week, the companies said.
"It clearly is a year of mergers for pharmaceutical companies," said Philippe Lanone, an analyst at Natixis Securities in Paris. "They don't have much of a choice if they are to guarantee EPS growth in the years to come."
Schering-Plough has medicines in late-stage testing that may generate more than US$6 billion in annual sales, the company said in November. Last month, Schering-Plough's earnings beat analyst estimates after it added sales from its acquisition of Organon BioSciences and reduced costs.
Under the terms of the deal, Schering-Plough shareholders will receive 0.5767 shares and US$10.50 in cash for each share of Schering-Plough. The cash portion will be financed with a combination of US$9.8 billion from existing cash balances and US$8.5 billion from financing to be provided by JPMorgan Chase & Co.
The price represents a premium of about 44 percent based on the average closing price of the two stocks over the past 30 trading days.
Merck shareholders are expected to own about 68 percent of the combined company, and Schering-Plough shareholders about 32 percent.
Schering-Plough co-markets anti-inflammatory drug Remicade with J&J, and developed cholesterol pills Vytorin and Zetia with Merck, Bloomberg News said.
Schering-Plough's most promising treatment in development, TRA, is designed to prevent blood clots with fewer side effects than older drugs and could come on the market as early as 2011.
Schering-Plough holders will get US$23.61 a share, a 34-percent premium to the closing stock price last week, the companies said.
"It clearly is a year of mergers for pharmaceutical companies," said Philippe Lanone, an analyst at Natixis Securities in Paris. "They don't have much of a choice if they are to guarantee EPS growth in the years to come."
Schering-Plough has medicines in late-stage testing that may generate more than US$6 billion in annual sales, the company said in November. Last month, Schering-Plough's earnings beat analyst estimates after it added sales from its acquisition of Organon BioSciences and reduced costs.
Under the terms of the deal, Schering-Plough shareholders will receive 0.5767 shares and US$10.50 in cash for each share of Schering-Plough. The cash portion will be financed with a combination of US$9.8 billion from existing cash balances and US$8.5 billion from financing to be provided by JPMorgan Chase & Co.
The price represents a premium of about 44 percent based on the average closing price of the two stocks over the past 30 trading days.
Merck shareholders are expected to own about 68 percent of the combined company, and Schering-Plough shareholders about 32 percent.
Schering-Plough co-markets anti-inflammatory drug Remicade with J&J, and developed cholesterol pills Vytorin and Zetia with Merck, Bloomberg News said.
Schering-Plough's most promising treatment in development, TRA, is designed to prevent blood clots with fewer side effects than older drugs and could come on the market as early as 2011.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
